Blog

Three-Day Polo Festival Welcomes Over 30,000 Global Attendees to Hurlingham Park

WEST PALM BEACH, FLA./LONDON, U.K. / ACCESS Newswire / June 10, 2025 / U.S. Polo Assn., the official brand of the United States Polo Association (USPA), proudly served once again as the Official Apparel and Jersey Partner for Chestertons Polo in the Park, one of the world’s largest and most iconic polo lifestyle festivals. Held June 6-8, 2025, at the historic Hurlingham Park in the heart of London, this year’s edition welcomed over 30,000 attendees across three thrilling days of international polo, sport-inspired fashion, and family-friendly entertainment.

As the Official Apparel and Jersey Partner, U.S. Polo Assn. outfitted all participating teams of the weekend, as well as staff uniforms. The brand also hosted an immersive on-site experience for event attendees, featuring a vibrant U.S. Polo Assn. merchandise tent showcasing official co-branded event apparel, a polo-inspired photo wall, and interactive brand models, along with contests and cap giveaways.

Now in its 15^th year, Chestertons Polo in the Park is the only polo event played in central London and continues to grow in prestige and popularity as Europe’s largest three-day polo and lifestyle event with action-packed polo games, food festivals, luxury shopping, entertainment, and more. The highly anticipated weekend kicked off with International Day on Friday, as England faced Argentina, alongside six world-class polo teams representing different global cities, followed by Saturday’s Ladies Day, and the culminating event on Sunday with Finals and Family Day, drawing crowds of polo enthusiasts from the U.K. and across the globe. Team Riyadh won the weekend’s tournament against Akrham Team Punta Cana with a score of 10-5, and Cesar Crespo from Team Riyadh was awarded Tournament MVP.

“Chestertons Polo in the Park is a one-of-a-kind event that brings together the spirit of polo, our U.S. Polo Assn. brand, and the energy of London in a fun, stylish, and accessible way,” said J. Michael Prince, President and CEO of USPA Global, the company that manages and markets the U.S. Polo Assn. brand. “Our sponsorship reinforces the authentic connection between our brand and the sport of polo while helping us further engage U.K. consumers in one of our most important and fastest-growing markets.”

The global, multi-billion-dollar U.S. Polo Assn. brand continues to expand across the United Kingdom with store openings at McArthurGlen’s East Midlands and Cheshire Oaks and additional brick-and-mortar locations planned in the coming years. U.K. consumers can also explore the brand’s latest sport-inspired styles for men, women, and children at www.uspoloassn.co.uk.

“As the strategic partner of U.S. Polo Assn. in the U.K., Chestertons Polo in the Park is an ideal platform to showcase our sport-inspired brand’s connection to historic English polo,” said Boo Jalil, CEO of Brand Machine Group, U.S. Polo Assn.’s U.K. licensing partner. “This annual celebration not only builds brand visibility in a meaningful way, but also highlights the fun, fashion-forward, and approachable spirit of U.S. Polo Assn.”

Set against the backdrop of one of polo’s most historic venues – Hurlingham Park, where the sport was first played in 1874, the event reflects decades of tradition, including hosting the 1908 Olympic Polo Final and multiple Westchester Cup matches between the United States and England.

“U.S. Polo Assn. is the perfect fit for Chestertons Polo in the Park, and we value the continued support,” said Rory Heron, Managing Director of Sportgate International, the founding organizer of the event. “The brand’s meaningful connection to the game and globally recognized style brings authenticity, accessibility, and innovative activations to our spectacular annual celebration of sport and lifestyle in London.”

Photo Captions:

1. Team Riyadh and Tournament MVP Cesar Crespo and Arkham Team Punta Cana’s Tommy Severn Battling for the Ball at Chestertons Polo in the Park Wearing the Iconic Double Horsement Logo From Apparel and Jersey Sponsor U.S. Polo Assn.

2. U.S. Polo Assn. Merchandise Pop-Up at Chestertons Polo in the Park

3. Event Attendees Posing With Models of Official Apparel Sponsor U.S. Polo Assn.

4. Chestertons Polo in the Park Player Noor Khadra Signing U.S. Polo Assn. Caps, Given Out at the Spectacular Three-Day Lifestyle Event

5. Beautiful Chestertons Polo in the Park Guests Posing in U.S. Polo Assn. Caps, Given Out at the Spectacular Three-Day Lifestyle Event

Photo Credit: Jen Deberigny

About U.S. Polo Assn.

U.S. Polo Assn. is the official brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890 and based at the USPA National Polo Center in Wellington, Florida. This year, U.S. Polo Assn. celebrates 135 years of sports inspiration alongside the USPA. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,100 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. Historic deals with ESPN in the United States and Star Sports in India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.

U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, NBA, and MLB, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global and digital growth. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ, as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world.

For more information, visit uspoloassnglobal.com and follow @uspoloassn.

About Brand Machine Group (BMG)

BMG is an international leader in fashion innovation which has established itself as a vertical manufacturer and global licensing specialist with over four decades of industry experience. Partnering with recognized market leaders, BMG manages a seamless and collaborative process of designing, manufacturing, and delivering quality products while championing the DNA of a diverse portfolio of brands, spanning fashion, sports, outdoor, and homeware including adult fashion, kidswear, and accessories.

BMG’s portfolio of brands includes U.S. Polo Assn. Penfield, New Balance Kids, Duchamp, Jack Wills, Flyers American Born, Lee Kids, Peckham Rye, Wrangler Kids, Juicy Couture, Franklin & Marshall, Elle Junior and Ben Sherman. BMG reaffirms its commitment to upholding sustainable and ethical business practices by ensuring full transparency throughout its global supply chain, aligning with the ETI Base Code.

Visit brandmachinegroup.com and follow @brandmachinegroup. For appointments, contact sales@brandmachinegroup.com.

About Sportgate International

Sportgate International is an international event management and sports marketing agency. Established in 2015, Sportgate International now owns events and consults with companies, luxury brands, world-class venues, tourism boards, and rights holders requiring sponsorship and event expertise. Sportgate International owns a portfolio of luxury events which encourages and enables the world’s best brands, top companies, and individuals to further their corporate or personal objectives. The company also works with some of the most high-profile venues in the world, offering original content that enables networking and marketing to specific audiences.

For more information, visit sportgateint.com.

SOURCE: U.S. Polo Assn.

Related Images

View the original press release on ACCESS Newswire

TORONTO, ON / ACCESS Newswire / June 10, 2025 / Northern Superior Resources Inc. (“Northern Superior” or the “Company“) (TSXV:SUP)(OTCQX:NSUPF)(GR:D9M1) is pleased to announce additional results from its 20,000-metre expansion drilling campaign at the Philibert gold property, located just 9 km from IAMGOLD Corporation’s (“IAMGOLD“) Nelligan project and 60 km southwest of Chibougamau, Quebec (the “Philibert Project“: Northern Superior: 75%, SOQUEM: 25%).

Highlights Include (Grades uncut; lengths measured along hole; see Table 1):

• PB-25-498: 4.82 g/t Au over 21.6 metres (583.0 m to 605.1 m), including 11.86 g/t Au over 7.0 metres (595.0 m to 602.0 m): located beneath and south of current resource and 200 metres along strike from new discovery in PB-25-484 with 2.48 g/t Au over 18.0 metres (620.0 m to 638.0 m), including 7.02 g/t Au over 4.9 metres (621.1 m to 626.0 m) (see press releases dated March 25, 2025);

• PB-25-501: 2.09 g/t Au over 22.2 metres (447.8 m to 470.0 m), including 3.54 g/t Au over 10.0 metres (460.0 m to 470.0 m), located beneath and south of the current resource pit 175 metres up dip of PB-25-498; and

• New Discovery Expanded Outside Current Resource Pit: These results, along with PB-25-484, now define a new high-grade zone over a 200-metre strike length and more than 150 metres of vertical extent.

“Discovering high-grade mineralization with strong continuity and scale is always meaningful-but finding it directly beneath an open-pit resource adds significant strategic value. It opens the door to a phased development approach, potentially improving project economics and strengthening the long-term outlook. These results continue to reinforce our view that Philibert has the potential to become a long-life asset with substantial upside,” said Simon Marcotte, President and Chief Executive Officer.

“These results reinforce the exceptional growth potential at Philibert and extend a new high-grade discovery that remains entirely outside the current open-pit resource envelope of 1.71 million ounces at 1.1 g/t Au (Inferred) and 279,000 ounces at 1.1 g/t Au (Indicated). With three holes now outlining a 200-metre strike and over 150 metres of vertical continuity, we are seeing clear potential to expand the mineralization and define a significant underground resource base. This area is quickly becoming a priority for future drilling, and our evolving geological and structural interpretation will be key in unlocking its full potential,” added Adree DeLazzer, Vice President of Exploration.

Drilling Results

Drillhole PB-25-498 intersected 4.82 g/t Au over 21.6 metres, including 11.86 g/t Au over 7.0 metres, from a downhole depth of 583 metres (~490 metres vertical). The mineralization is over 200 metres east of the previously announced hole PB-25-484 which may represent a new zone or a down-plunge extension of the fault gap foot wall (“FW“) zone. Historic drilling suggested deeper potential, with nearby intercepts located 190 metres up-dip and 150 metres along strike (see Table 1 and Figures 1, 2, 3, 4, and 5, as well as Figure 6 for a core photo of PB-25-498). Some narrow intersections were returned for the hanging wall (“HW“) zone and 0.47 g/t Au over 6.5 metres starting at 437.5 metres from the fault gap FW zone.

Drillhole PB-25-501 intersected 2.09 g/t Au over 22.2 metres, including a higher-grade interval of 3.54 g/t Au over 10.0 metres, from a downhole depth of 478.0 metres. The intersection is located between holes PB-25-498 and 484 (100 metres along strike) and over 100 metres up dip. The mineralized zone occurs at 400 metres vertical depth, or approximately350 metres beneath the current resource pit shell (see Table 1 and Figures 1, 2, 3, 4, and 5). The HW zone was also intersected in this hole returning 0.64 g/t Au over 10.5 metres starting at 34.5 metres. Down dip of the fault gap FW zone the hole returned a narrow intersection of 1.30 g/t Au over 2.4 metres starting at 310.6 metres.

Drillholes PB-25-483, collared 120 metres south and up-dip of PB-25-501, returned 0.41 g/t Au over 23.7 metres starting at 223.0 metres from fault gap FW zone including 1.47 g/t Au over 3.3 metres and may have intersected the up-dip extension of the new discovery zone near the end of the hole, which the Company plans to extend (see Table 1 and Figures 1, 2, 3, 4, and 5). The HW zone was also intersected in this drill hole returning 0.51 g/t Au over 8.0 metres starting at 58.0 metres.

PB-25-482 drilled 280 metres south and 40 metres west of PB-25-498, intersected 0.76 g/t Au over 10.0 metres starting at 322.0 metres, approximately 50 metres below the resource pit. This interval may represent the up-dip projection of the new discovery zone. Additional extension drilling is planned. The drill hole also intersected a zone down dip of the fault gap FW zone returning 0.59 g/t Au over 1.6 metres starting at 245.7 metres (see Table 1 and Figures 1, 2, 3, 4, and 5).

Gold mineralization is hosted within the siliceous phase of the Philibert gabbro seam, characterized by pervasive silicification, quartz veining, albite, ankerite and sericite alteration, and 1-15% disseminated pyrite-pyrrhotite.

Table 1: Significant Drillhole Intersections for the Current Press Release

DDH ID	From (m)	To (m)	Width (m)	Au Finale (g/t)	Comment
PB-25-482	24.3	25.5	1.2	0.99	Fault Gap HW
and	79.5	80.8	1.3	1.10	Fault Gap HW
and	89.0	90.0	1.0	0.57	Fault Gap HW
and	111.0	112.0	1.0	0.55	Fault Gap HW
and	245.7	247.3	1.6	0.59	Fault Gap FW
and	312.0	315.0	3.0	0.54	FW – New Zone
and	322.0	332.0	10.0	0.76	FW – New Zone
PB-25-483	58.0	66.0	8.0	0.51	Fault Gap HW
and	223.4	247.1	23.7	0.41	Fault Gap FW
including	243.8	247.1	3.3	1.41
and	271.5	273.0	1.5	1.12	Fault Gap FW
and	322.0	352.5	30.5	0.36	FW – New Zone
including	333.0	342.5	9.5	0.64
PB-25-498	60.5	66.5	6.0	0.46	Fault Gap HW
and	74.9	77.4	2.5	0.96	Fault Gap HW
and	154.6	157.5	2.9	0.65	Fault Gap HW
and	437.5	444.0	6.5	0.47	Fault Gap FW
and	583.5	605.1	21.6	4.82	FW – New Zone
including	595.0	602.0	7.0	11.86	FW – New Zone
PB-25-501	34.5	45.0	10.5	0.64	Fault Gap HW
and	310.6	313.0	2.4	1.30	Fault Gap HW
and	447.8	470.0	22.2	2.09	FW – New Zone
including	460.0	470.0	10	3.54	FW – New Zone
including	461.0	467.5	6.5	4.82	FW – New Zone
and	484.5	489.5	5.0	0.59	FW – New Zone

Grades have not been capped in the averaging and intervals are reported as drill thickness. True widths are estimated at 70% to 90%. Intersections are determined using 0.3 g/t Au cut off and no more than 15 metres of consecutive dilution. If an intersection is 1 metre or less dilution under 0.1 g/t Au may be used to determine a 2-metre intersection.

Table 2: Drill-Hole Collars and Parameters

HOLE-ID	Easting	Northing	Azimuth	Dip	Elevation (m)	Length (m)
PB-25-482	528887	5480828	210	-47	375	390.0
PB-25-483	528805	5480846	210	-60	375	401.8
PB-25-498	529066	5481050	210	-55	375	648.0
PB-25-501	528862	5480947	210	-60	375	555.0

The Chibougamau Gold Camp

The Chibougamau Gold Camp is rapidly emerging as one of the world’s most sought-after gold destinations with several complementary gold resources reaching viable scale. In recent years, these critical assets were divided amongst five different companies. Today, largely due to Northern Superior’s acquisitions and corporate transactions,² ownership has been streamlined, with only IAMGOLD and Northern Superior holding these assets. The proximity of these deposits to each other makes them ideally suited to feed a single mill, and their consolidation enhances their viability, thereby increasing their value.

Below is a table showing the resources of the camp having been formalized to date.

Qualified Person (“QP”)

The technical content and drilling results contained in this news release have been prepared in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects (“NI 43-101“) and have been reviewed and approved by Ms. Melanie Pichon, P.Geo., Senior Geologist for Northern Superior. Ms. Pichon is a QP under the NI 43-101 and is not considered independent.

Northern Superior adheres to strict protocols following the NI 43-101 best practices when conducting exploration works. Sampling and assay results are monitored with strict QAQC protocols. Drilled core is processed and assayed in Northern Superior’s facilities in Chapais, Quebec. Core samples (half core) of NQ drill core are transported to Agat Laboratory in Val d’Or. Samples are analyzed by fire assay with a 50-gram charge with an Atomic Absorption (AA) finish. Samples returning assay values over 10.0 grams are re-assayed with a gravimetric finish. QAQC consists of 4% of blank material, certified standards and duplicates inserted in the assay sequences by Northern Superior.

About Northern Superior Resources Inc.

Northern Superior is a gold exploration company focused on the Chibougamau Camp in Québec, Canada. The Company has consolidated the largest land package in the region, with total land holdings currently exceeding 62,000 hectares. The main properties include Philibert, Lac Surprise, Chevrier, and Croteau. Northern Superior also owns 56% of ONGold Resources Ltd. (TSXV: ONAU) (OTCQX: ONGRF) which is advancing promising exploration assets in Northern Ontario and Manitoba, including the district scale TPK Project and Monument Bay; Agnico Eagle Mines Limited owns 15% of ONGold Resources Ltd.

The Philibert Project is located 9 km from IAMGOLD Corporation’s Nelligan³ Gold project. Philibert hosts a maiden 43-101 inferred resource of 1,708,800 ounces Au and an indicated resource of 278,900 ounces Au.⁴ Northern Superior holds a majority stake of 75% in the Philibert Project, with the remaining 25% owned by SOQUEM, and retains an option to acquire the full 100% ownership of the project. Chevrier hosts an inferred mineral resource of 652,000 ounces Au (underground and open pit) and an indicated mineral resource of 260,000 ounces Au.⁵ Croteau hosts an inferred mineral resource of 640,000 ounces Au.⁶ Lac Surprise hosts the Falcon Zone Discovery, interpreted to be the western strike extension of IAMGOLD Corporation’s Nelligan Gold project.

Northern Superior is a reporting issuer in British Columbia, Alberta, Ontario and Québec, and trades on the TSXV under the symbol SUP and the OTCQB Venture Market under the symbol NSUPF. For further information, please refer to the Company’s website at www.nsuperior.com or the Company’s profile on SEDAR+ at www.sedarplus.ca.

About SOQUEM

SOQUEM, a subsidiary of Investissement Québec, is dedicated to promoting the exploration, discovery, and development of mining properties in Québec. SOQUEM also contributes to maintaining strong local economies. Proud partner and ambassador for the development of Québec’s mineral wealth, SOQUEM relies on innovation, research, and strategic minerals to be well-positioned for the future.

Northern Superior Resources Inc. on Behalf of the Board of Directors

Simon Marcotte, CFA, President and Chief Executive Officer

Contact Information

Katrina Damouni
Director – Corporate Development
Tel: +44 7795 128583 (Mobile/WhatsApp)
info@nsuperior.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

^{1 PB-25-498: 21.6 metres from 583.5 m to 605.1 m at 4.82 g/t Au including 7.0 metres from 595.0 m to 602.0 metres at 11.86 g/t Au; PB-25-501: 22.2 metres from 447.8 to 470.0 m at 2.09 g/t Au including 10.0 m from 460.0 m to 470.0 m at 3.54 g/t Au.}

^{2 Including Northern Superior’s acquisitions of Genesis Metals Corp. and Royal Fox Gold Inc.}

^{3 “lAMGOLD Announces Significant Increase in Nelligan Ounces & Update of Global Mineral Reserves and Resources”; IAMGOLD reports increase in mineral reserves and resources at existing assets, with increase in resources at Gosselin; IAMGOLD Corporation News Release dated February 15, 2024, October 23, 2024, and February 20, 2025. Note that the technical and scientific information disclosed from neighboring properties does not apply to any other properties of the area.}

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of the applicable Canadian securities legislation that is based on expectations, estimates, projections and interpretations as at the date of this news release. The information in this news release about the proposed transaction; and any other information herein that is not a historical fact may be “forward-looking information”. Any statement that involves discussions with respect to predictions, expectations, interpretations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “interpreted”, “management’s view”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward- looking information and are intended to identify forward-looking information. This forward-looking information is based on reasonable assumptions and estimates of management of Northern Superior, at the time it was made, involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the companies to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others, risks relating to the ability of the parties to execute the proposed transaction. Although the forward-looking information contained in this news release is based upon what management believes, or believed at the time, to be reasonable assumptions, the parties cannot assure shareholders and prospective purchasers of securities that actual results will be consistent with such forward-looking information, as there may be other factors that cause results not to be as anticipated, estimated or intended, and neither party nor any other person assumes responsibility for the accuracy and completeness of any such forward-looking information. Neither party undertakes, and assumes no obligation, to update or revise any such forward-looking statements or forward-looking information contained herein to reflect new events or circumstances, except as may be required by law.

SOURCE: Northern Superior Resources Inc.

View the original press release on ACCESS Newswire

Early surface reconnaissance and drilling progress sharpen silver focus

HIGHLIGHTS

• Current ~2,500m reverse circulation (RC) drilling program underway at Tolmer discovery; planned gold drilling reallocated to prioritise silver zone following early observations¹

• Additional target holes added north, east, south and west of high-grade ‘discovery line’²

ADELAIDE, AUSTRALIA / ACCESS Newswire / June 9, 2025 / Barton Gold Holdings Limited (ASX:BGD)(FRA:BGD3)(OTCQB:BGDFF) (Barton or Company) is pleased to provide an update for RC drilling underway at its recent ‘Tolmer’ high grade silver discovery, located at the Company’s South Australian Tarcoola Gold Project (Tarcoola).¹ Drilling recently started at Tolmer with a priority focus on the western ‘silver zone’.¹ Planned gold drilling will now be deferred in favour of extending drilling at the silver zone, ahead of anticipated follow-up programs starting as early as late July.

Figure 1 – Tolmer ‘western silver’ & ‘eastern gold’ zones showing expanded silver drilling lines

Commenting on the revised drilling program, Barton Managing Director Alexander Scanlon said:

“Based upon early observations we are refocusing all current Tolmer drilling on the western ‘silver zone’. We will expedite these assays to inform near-term follow-up programs, likely to include orientation diamond drilling.”

Growing ‘silver zone’ footprint

Barton identified Tolmer as a high-grade gold discovery in August 2024, and subsequently identified a new ‘silver zone’ ~500m west in a line of seven discovery holes with globally significant assays including:³

Hole ID	Interval	Including:
TBAC130	6m @ 4,747 g/t Ag from 46 metres	1m @ 17,600 g/t Ag from 46 metres
TBM227	4m @ 1,417 g/t Ag from 9 metres	1m @ 3,790 g/t Ag from 9 metres
TBM228	14m @ 434 g/t Ag from 46 metres	1m @ 3,350 g/t Ag from 54 metres

On 22 May Barton commenced a planned program of ~2,500m RC drilling which was designed to infill and extend both the western ‘silver zone’ and the eastern ‘gold zone’.⁴ Based upon further geological surface reconnaissance and early observations from drilling, it was decided to expand the ‘silver zone’ drilling program to gather a larger amount of data on this area with the remaining time available in this program.

Seven drill holes originally planned for the eastern ‘gold zone’ have been re-allocated to eight new drill holes in the western ‘silver zone’, expanding the planned drilling from three to five lines of RC holes. The total Tolmer drilling program has been expanded from a planned ~2,500m to a revised total of ~2,850m.

Drilling of the expanded ‘silver program’ is now anticipated to finish this week, following which assays will be expedited for laboratory analysis and planning of follow up drilling programs. These will likely include additional RC drilling (including in the gold zone) and diamond drilling for structural orientation.

Figure 2 – Tolmer ‘silver zone’ cross-section (see Fig. 2) with anomalous Ag-Pb and key intersections⁴

^{1 Refer to ASX announcement dated 22 May 2025}

^{2 Refer to ASX announcements dated 27 August 2024 and 30 January, 27 March, 16 April and 12 / 22 May 2025}

^{3 Refer to ASX announcements dated 27 August 2024 and 30 January, 6 February, 27 March, 16 April and 22 May 2025}

^{4 Refer to ASX announcement dated 22 May 2025}

Authorised by the Managing Director of Barton Gold Holdings Limited.

For further information, please contact:

Alexander Scanlon Managing Director a.scanlon@bartongold.com.au +61 425 226 649

Jade Cook Company Secretary cosec@bartongold.com.au +61 8 9322 1587

About Barton Gold

Barton Gold is an ASX, OTCQB and Frankfurt Stock Exchange listed Australian gold developer targeting future gold production of 150,000ozpa with 1.7Moz Au & 3.1Moz Ag JORC Mineral Resources (64.0Mt @ 0.83 g/t Au), brownfield mines, and 100% ownership of the region’s only gold mill in the renowned Gawler Craton of South Australia.

Tarcoola Gold Project Fully permitted open pit mine with ~20koz Au within trucking distance of Barton’s Central Gawler Mill Historical goldfield with new high-grade gold-silver discovery in grades up to 83.6 g/t Au and 17,600 g/t Ag Tunkillia Gold Project 1.6Moz Au & 3.1Moz Ag JORC Mineral Resources Optimised Scoping Study for competitive ~120kozpa gold and ~250kozpa silver bulk open pit operation Key Regional Infrastructure Region’s only gold processing plant (650ktpa CIP) Multiple camps / accommodation across projects

Competent Persons Statement & Previously Reported Information

The information in this announcement that relates to the historic Exploration Results and Mineral Resources as listed in the table below is based on, and fairly represents, information and supporting documentation prepared by the Competent Person whose name appears in the same row, who is an employee of or independent consultant to the Company and is a Member or Fellow of the Australasian Institute of Mining and Metallurgy (AusIMM), Australian Institute of Geoscientists (AIG) or a Recognised Professional Organisation (RPO). Each person named in the table below has sufficient experience which is relevant to the style of mineralisation and types of deposits under consideration and to the activity which he has undertaken to quality as a Competent Person as defined in the JORC Code 2012 (JORC).

Activity	Competent Person	Membership	Status
Tarcoola Mineral Resource (Stockpiles)	Dr Andrew Fowler (Consultant)	AusIMM	Member
Tarcoola Mineral Resource (Perseverance Mine)	Mr Ian Taylor (Consultant)	AusIMM	Fellow
Tarcoola Exploration Results (until 15 Nov 2021)	Mr Colin Skidmore (Consultant)	AIG	Member
Tarcoola Exploration Results (after 15 Nov 2021)	Mr Marc Twining (Employee)	AusIMM	Member
Tunkillia Exploration Results (until 15 Nov 2021)	Mr Colin Skidmore (Consultant)	AIG	Member
Tunkillia Exploration Results (after 15 Nov 2021)	Mr Marc Twining (Employee)	AusIMM	Member
Tunkillia Mineral Resource	Mr Ian Taylor (Consultant)	AusIMM	Fellow
Challenger Mineral Resource	Mr Dale Sims (Consultant)	AusIMM / AIG	Fellow / Member

The information relating to historic Exploration Results and Mineral Resources in this announcement is extracted from the Company’s Prospectus dated 14 May 2021 or as otherwise noted in this announcement, available from the Company’s website at www.bartongold.com.au or on the ASX website www.asx.com.au. The Company confirms that it is not aware of any new information or data that materially affects the Exploration Results and Mineral Resource information included in previous announcements and, in the case of estimates of Mineral Resources, that all material assumptions and technical parameters underpinning the estimates, and any production targets and forecast financial information derived from the production targets, continue to apply and have not materially changed. The Company confirms that the form and context in which the applicable Competent Persons’ findings are presented have not been materially modified from the previous announcements.

Cautionary Statement Regarding Forward-Looking Information

This document may contain forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “expect”, “target” and “intend” and statements than an event or result “may”, “will”, “should”, “would”, “could”, or “might” occur or be achieved and other similar expressions. Forward-looking information is subject to business, legal and economic risks and uncertainties and other factors that could cause actual results to differ materially from those contained in forward-looking statements. Such factors include, among other things, risks relating to property interests, the global economic climate, commodity prices, sovereign and legal risks, and environmental risks. Forward-looking statements are based upon estimates and opinions at the date the statements are made. Barton undertakes no obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates or to update or keep current any of the information contained herein. Any estimates or projections as to events that may occur in the future (including projections of revenue, expense, net income and performance) are based upon the best judgment of Barton from information available as of the date of this document. There is no guarantee that any of these estimates or projections will be achieved. Actual results will vary from the projections and such variations may be material. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. Any reliance placed by the reader on this document, or on any forward-looking statement contained in or referred to in this document will be solely at the readers own risk, and readers are cautioned not to place undue reliance on forward-looking statements due to the inherent uncertainty thereof.

* Refer to Barton Prospectus dated 14 May 2021 and ASX announcement dated 4 March 2025. Total Barton JORC (2012) Mineral Resources include 909koz Au (30.8Mt @ 0.92 g/t Au) in Indicated category and 799koz Au (33.2Mt @ 0.75 g/t Au) in Inferred category, and 3,070koz Ag (34.5Mt @ 2.80 g/t Ag) in Inferred category as a subset of Tunkillia gold JORC (2012) Mineral Resources.

SOURCE: Barton Gold Holdings Limited

View the original press release on ACCESS Newswire

Click here to register

Discussion will focus on company’s May 2025 meeting with the FDA to review the statistically significant responder analysis results for the subgroup of breast cancer patients in company’s recently conducted Phase 3 OnTarget trial

The currently estimated US metastatic breast cancer population potentially qualifies as an orphan population, in alignment with company’s core focus on orphan diseases

Company plans to promptly pursue authorization to initiate expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / June 9, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today issued a reminder that Lisa Conte, the company’s founder, president and CEO, will participate in a virtual fireside chat at 9:00 AM Eastern tomorrow, Tuesday, June 10, 2025, as part of Lytham Partners’ spring 2025 Spotlight Series.

Participation Instructions for Jaguar Health’s Virtual Fireside Chat During Lytham Partners Spring 2025 Spotlight Series

When: Tuesday, June 10, 2025 from 9:00 – 10:00 AM Eastern

Where: Online (Click Here). The fireside chat will also be available for replay following the event.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo’s crofelemer is FDA-approved under the brand name Mytesi^® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that Jaguar management will participate in a virtual fireside chat June 10, 2025 as part of Lytham Partners’ spring 2025 Spotlight Series, Jaguar’s expectation that the currently estimated US metastatic breast cancer population may qualify as an orphan population, and Jaguar’s expectation that it will promptly pursue authorization to initiate an expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer patients. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Source: Jaguar Health, Inc.

Contact:

hello@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / June 9, 2025 / Commercialville.TV, the internet’s first and only zip-code-targeted, video-based search engine, has officially launched with a bold, integrated media campaign including Times Square billboard exposure, a feature release on the New to The Street TV YouTube Channel, and a continuing national broadcast television rollout across Fox Business and Bloomberg Television.

Built to revolutionize the way consumers connect with businesses, Commercialville.TV combines hyper-local precision with 100% advertiser-generated video content (AGC). Users simply enter a zip code and keyword to receive instant video search results from businesses in that exact location-eliminating irrelevant results and wasted time.

The platform’s patented Instant Adification Playbox™ enables viewers to interact with businesses directly from the same page-bringing search, discovery, and conversion into one seamless experience.

“We’re bringing location-specific video search into the modern age,” said Paul Lawrence, Founder of Commercialville.TV. “This is the first platform built entirely around local video visibility and instant engagement. Our mission is to help businesses get discovered faster and more meaningfully-while giving users exactly what they want, where they want it.”

The launch is supported by a prominent 42nd Street billboard campaign in Times Square, exposing the brand to millions of daily viewers. The rollout continues across national television via New to The Street, a leading financial media platform known for amplifying growth-stage companies across broadcast, digital, and outdoor media.

WATCH THE FULL FEATURE NOW:
https://youtu.be/4b8WCfWoFH8?si=CsQnDhec81i202Ki

Upcoming National Broadcast Airings:

• Fox Business – Air Date T.B.A.

• Bloomberg Television – Air Date T.B.A.

• YouTube Premiere: Now streaming on New to The Street TV

About Commercialville.TV

Commercialville.TV is the world’s first zip-code-targeted, video-based search engine, built to help users find exactly what they want, exactly where they want it-fast. With its patented Instant Adification Playbox™ and exclusive Advertiser Generated Content (AGC) model, the platform transforms traditional search into a visual-first, hyper-local discovery experience. Founded by media innovator Paul Lawrence, Commercialville.TV is reshaping how businesses reach new customers and how consumers connect with local services and products.

Visit www.Commercialville.TV

About New to The Street

New to The Street is one of America’s longest-running business media platforms, broadcasting weekly across Fox Business and Bloomberg Television as sponsored programming. Reaching over 245 million homes and boasting a YouTube channel with more than 2.5 million subscribers, New to The Street helps emerging brands and public companies tell their stories through long-form interviews, earned media, and multi-channel visibility. With additional exposure through Times Square billboards and national syndication, it is the go-to platform for media amplification.

For more information, visit www.NewToTheStreet.com

Media Contact:

Monica Brennan
New to The Street Media Relations
Monica@NewtoTheStreet.com

SOURCE: New To The Street

View the original press release on ACCESS Newswire

SAN DIEGO, CA / ACCESS Newswire / June 9, 2025 / The United Kingdom’s Ministry of Defence has signed a support and sustainment contract with General Atomics Aeronautical Systems, Inc. (GA-ASI) for logistics and maintenance of the Protector RG Mk1 Remotely Piloted Aircraft (RPA) system. The contract – known as the UK Protector Availability and Support Solution or UK PASS – will provide ongoing support for the new Protector RPA systems supplied by GA-ASI and now being operated by the UK’s Royal Air Force (RAF). The Protector RPA is based on GA-ASI’s MQ-9B SkyGuardian^®.

UK PASS is a Direct Commercial Sale contract and includes support for the Protector program’s RPA, the Certifiable Ground Control Stations and the Synthetic Training Systems.

“This contract marks an essential milestone in the fielding of the Protector RPA system for the RAF,” said Chris Dusseault, Vice President of MQ-9B in Europe. “With the UK PASS contract in place, we can now transition from the test and development phase of the program to training the RAF flight crews for operations.”

UK PASS is part of GA-ASI’s SkyGuardian Global Support Solutions (SGSS), which provides support for the entire MQ-9B customer base. SGSS is a shared Contractor Logistics Support (CLS) model, with resources such as labor, material, and overhead for maintenance, supply management, and other support functions required to sustain the RPA system, pooled together for use by the entire customer base. This approach provides efficiencies and a lower cost for customers.

“The awarding of the PASS contract marks three years of intensive work between GA-ASI and UK MOD multidisciplinary teams to turn a concept in to a reality. This has generated a first-in class sustainment solution for the Royal Air Force Protector fleet, that exploits contractor owned inventory from a global common spares pool. This contract differs from a traditional spares and repairs contract, achieving economies of scale via a multi-customer common operating model,” said Group Captain Rich Cameron – Uncrewed Air System 3 Team Leader.

GA-ASI’s MQ-9B is the world’s most advanced RPA system, delivering exceptionally long endurance and range. MQ-9B includes the SkyGuardian and SeaGuardian^® models, with multiple deliveries made to the U.K.’s Royal Air Force (Protector), as well as orders from Canada, Poland, the Japan Coast Guard, the Japan Maritime Self-Defense Force, Taiwan, India, and the U.S. Air Force in support of the Special Operations Command. MQ-9B has also supported various U.S. Navy exercises, including Northern Edge, Integrated Battle Problem, and Group Sail.

About GA-ASI

General Atomics Aeronautical Systems, Inc., is the world’s foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 8 million flight hours, the Predator^® line of UAS has flown for over 30 years and includes MQ-9A Reaper^®, MQ-1C Gray Eagle^® 25M, MQ-20 Avenger^®, and MQ-9B SkyGuardian^®/SeaGuardian^®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.

For more information, visit www.ga-asi.com.

Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.

Contact Information:

GA-ASI Media Relations
asi-mediarelations@ga-asi.com
(858) 524-8101

SOURCE: General Atomics Aeronautical Systems, Inc.

View the original press release on ACCESS Newswire

Row64’s interactive visual analysis of big data enables immediate response to rapidly changing conditions and emerging opportunities

CHEYENNE, WY / ACCESS Newswire / June 9, 2025 / Row64, creators of the only visual real-time business intelligence platform for big data, today announced its $4 million seed funding round led by Galaxy Interactive, with participation from Alumni Ventures and Differential Ventures. Based on the momentum from market traction across various industries, the capital will further fuel the expansion of Row64’s development roadmap and go-to-market teams, accelerating product innovation and global market adoption.

In today’s fast-paced, data-driven economy, enterprises face an overwhelming surge in the volume, velocity, and variety of data. Yet most legacy business intelligence systems are not equipped to deliver the real-time, visual insights needed to act on that information as it happens. As a result, organizations often miss critical opportunities or react too late to rapidly changing conditions. With global data creation expected to surpass 400 terabytes per day (the equivalent of 20 trillion high-res photos), solving this challenge has become essential to maintaining a competitive edge.

Row64 is the only visual real-time business intelligence platform delivering interactive analysis for massive data sets. Built on a GPU- and CPU-accelerated computing stack, Row64’s high-throughput, low-latency processing updates data at sub-millisecond speeds while powering a new generation of highly interactive dashboards. As a result, businesses can react faster to changing conditions and take advantage of opportunities as they arise.

“Real-time is the new standard for modern business intelligence,” said Marc Stevens, CEO and co-founder of Row64. “With our platform, enterprise customers can visualize and interact with massive, and even streaming, datasets instantly, empowering them to make the critical, fast-paced decisions that drive competitive advantage.”

Row64 next-generation dashboards are built from the ground up to push the boundaries of scalability and real-time performance. Utilizing Row64’s native browser front end powered by Web Assembly (WASM) and WebGL, users across the organization interact with GPU-rendered dashboards with detail and accuracy, capable of compositing rich data such as 2D and 3D GIS data, images, and line networks, all at ultra-high resolution (4k and 8k monitors) and interactive (60fps+) frame rates on billion-record datasets.

Key benefits of Row64 include:

• High throughput for real-time analysis and interactive visualization of massive datasets

• Instantly drill down from summary to record-level detail

• Access up-to-date information across the organization with industry standards and well-known interfaces

• Integrates with file management to support a variety of data-rich file types (e.g. PDF and DWG)

• Open and extensible for easy integration into existing IT environments and data pipelines, for on-prem, cloud, or hybrid deployment

• Low-latency, real-time event streaming

• Simple, transparent licensing based on compute needs

“Galaxy Interactive invests in transformative technologies and outstanding teams, and is proud to back Row64 as it builds a new full stack and defines a new category in business intelligence,” said Jeff Brown, Partner at Galaxy Interactive. “Their visual, real-time business intelligence platform solves a critical market gap, transforming how data-driven organizations operate in high-velocity environments.”

Row64’s speed, scale, flexibility, and visual precision support a wide range of use cases, including multivariate P&L analysis, spatial analytics for intelligent cities, real-time cybersecurity, motion analysis, HR organizational analysis, and complex systems analysis for emergency incident reporting.

Highlighting another industry first, Row64 will demonstrate its breakthrough new DeltaStream-powered Apache Kafka data pipeline for low latency, real-time data streaming, and interactive analysis, at the Databricks Summit in San Francisco, June 9-10. 2025 (Booth #F615).

For more information or to schedule a demo, visit www.row64.com.

ABOUT ROW64:

Row64 provides the world’s first visual real-time business intelligence platform, empowering the enterprise to gain immediate insights from massive datasets. Built on an accelerated computing stack, Row64 allows its customers to visualize and interact with big data instantly, enabling immediate, informed decision-making across the enterprise. Learn more at https://row64.com/.

ABOUT GALAXY INTERACTIVE:

Galaxy Interactive invests in transformative technology, content, and the infrastructure powering the convergence of our digital and physical lives. We back companies at the forefront of interactive content, spatial computing, edge AI, and real-time data protocols and invest across the full compute stack – from edge silicon to cloud. It was founded in 2018 and is based in New York, New York. Learn more at https://interactive.galaxy.com/.

MEDIA CONTACT:

Nina Pfister, MAG PR
nina@mooringadvisorygroup.com

SOURCE: Row64

View the original press release on ACCESS Newswire

Productive and collaborative discussion on proposed pathway by the company to bring crofelemer to approval for cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies

The currently estimated US metastatic breast cancer population would qualify as an orphan population, which aligns with company’s core focus on orphan diseases

Company plans to promptly pursue authorization to initiate expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer

SAN FRANCISCO, CA / ACCESS Newswire / June 9, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today provided a recap on the company’s assessment of the in-person Type C Meeting on May 28, 2025 with the Division of Gastroenterology of the U.S. Food and Drug Administration (FDA) to discuss the statistically significant responder analysis results for adult patients with breast cancer in Napo’s recently conducted Phase 3 OnTarget trial.

“We were very happy to take part in the face-to-face Type C Meeting, the catalyst for which was the positive data in the subpopulation of breast cancer patients from our OnTarget trial,” said Lisa Conte, Jaguar’s founder, president, and CEO. “Napo proposed two simultaneous potential pathways during the meeting for making crofelemer available to metastatic breast cancer patients with the significant unmet medical need of CTD: conducting a pivotal treatment trial to facilitate approval of crofelemer for CTD in this focused patient population; and the prompt pursuit of authorization to initiate an expanded access program for breast cancer patients with CTD who may not be eligible for this study, including breast cancer patients in the adjuvant and neoadjuvant settings. We are pleased with the constructive and productive discussion that took place with the FDA during the meeting. Last week the FDA formally acknowledged both of these key discussion points in correspondence to Napo. We plan to submit a protocol to the FDA for a pivotal treatment trial for a smaller number of metastatic breast cancer patients using crofelemer.”

Patient advocates participated in the Type C Meeting to share their raw and personal experience with CTD, including a metastatic breast cancer patient with uncontrollable diarrhea who received a prescription for crofelemer.

“The design of the protocol for OnTarget was based on a survey of cancer patients. Today there are close to 100 approved targeted cancer agents. Thanks to these amazing drugs, metastatic cancer patients are living longer, frequently rendering cancer, and CTD, chronic ailments with which to live. To deepen our understanding of the current population of metastatic cancer breast with CTD, and ensure the clinical meaningfulness of the design of the anticipated pivotal treatment trial, we plan to conduct a new survey of this cancer patient population,” Conte said.

The currently estimated US metastatic breast cancer population potentially qualifies as an orphan population, in alignment with the company’s core focus on orphan diseases. The company therefore intends to request orphan drug designation from the FDA for the CTD indication in this population. Given crofelemer’s novel and paradigm-shifting mechanism of action, the company also plans to seek Breakthrough Therapy designation and/or Fast Track designation from the FDA to support potentially expedited regulatory approval in the US for crofelemer for CTD in metastatic breast cancer patients.

“Embracing a sharp strategic focus on orphan indications seems to fit with the new administration’s efforts and philosophy,” said Conte. “Dr. Marty Makary, the new Commissioner of the FDA, commented in April 2025 that the agency will open a new regulatory pathway based on what he called a ‘plausible mechanism,’ focusing mainly on rare or incurable diseases.”

As expressed during the Type C Meeting, the data from the first-of-its-kind prophylactic OnTarget study is invaluable, providing new insights into the natural history of the important and debilitating side effect of CTD. Diarrhea is a common side effect of targeted cancer therapies and can lead to dose changes, treatment delays, and often cessation of lifesaving cancer therapy. The benefit to risk ratio of crofelemer is well-documented, as the active agent has been commercialized for the approved indication of HIV-related diarrhea since 2012, with no crofelemer-related reported serious adverse events.

In both the US and European Union, crofelemer has been granted orphan drug designation for the orphan diseases of short bowel syndrome with intestinal failure and microvillus inclusion disease. Crofelemer has been granted orphan drug designation for treatment of diarrhea in cholera in the US, where cholera is an orphan disease. Orphan drug designation in the US qualifies the sponsor of a drug for various development incentives, including tax credits for qualified clinical testing and relief of filing fees. Additionally, orphan drug designation in the US provides a seven-year period of marketing exclusivity to the first sponsor who obtains marketing approval for the designated orphan drug.

While the multicenter, double-blind, placebo-controlled OnTarget pivotal trial did not meet its primary endpoint, the subgroup of adult breast cancer patients achieved statistically significant results in the responder analysis. In the responder analysis of patients with breast cancer on targeted therapies, crofelemer CTD prophylaxis resulted in a greater proportion of monthly responders of diarrhea improvement compared to placebo. Patients with breast cancer accounted for 183 of the 287 participants in this unprecedented prophylactic clinical trial of crofelemer for diarrhea in adults with 10 solid tumor types receiving targeted therapy with or without standard chemotherapy.

The OnTarget results in breast cancer patients were the subject of a poster presentation on December 11, 2024, at the San Antonio Breast Cancer Symposium, and additional significant results in adult breast cancer patients from the OnTarget study have been accepted for presentation as an oral rapid e-poster at the Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting in June 2025 in Seattle, Washington.

About Crofelemer

Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as “dragon’s blood,” of the Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo’s crofelemer is FDA-approved under the brand name Mytesi^® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that the currently estimated US metastatic breast cancer population qualifies as an orphan population, Jaguar’s expectation that the company will submit a protocol to the FDA for a pivotal treatment trial for a smaller number of metastatic breast cancer patients using crofelemer, Jaguar’s expectation that it will promptly pursue authorization to initiate an expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer patients, and that the expanded access program would potentially include breast cancer patients in the adjuvant and neoadjuvant settings, Jaguar’s expectation that Napo will conduct a clinical trial of crofelemer for treatment of CTD in patients with metastatic breast cancer, Jaguar’s plans to seek Breakthrough Therapy designation and/or Fast Track designation from the FDA to support potentially expedited regulatory approval in the US for crofelemer for CTD in metastatic breast cancer patients, and Jaguar’s expectation that additional significant results in adult breast cancer patients from the OnTarget study will be presented at the 2025 MASCC Annual Meeting. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

PetVivo and Acurx Pharmaceuticals Exceed 200,000 Views as investor Demand for Long-Form Corporate Storytelling Surges

NEW YORK CITY, NEW YORK / ACCESS Newswire / June 9, 2025 / New to The Street, the nation’s leading financial media brand for long-form investor communications, proudly announces record-breaking viewership across its newest documentary-style programs. Its latest feature on IMG Academy surpassed 126,000 views in only 12 days on YouTube, marking a new milestone for the brand’s flagship long-form format.

Meanwhile, features on PetVivo Holdings, Inc. (NASDAQ:PETV) and Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) have crossed 200,000 views, reinforcing New to The Street‘s position as a go-to media platform for delivering cinematic, investor-focused storytelling at scale.

Watch the full specials here:

• IMG Academy: https://www.youtube.com/watch?v=k2YSY802cXk

• PetVivo: https://www.youtube.com/watch?v=3aVfrdEpchQ

• Acurx Pharmaceuticals: https://www.youtube.com/watch?v=jaJMKUEuU14

“These are not typical interviews-they’re broadcast-quality mini-documentaries that resonate across investor and consumer audiences alike,” said Vince Caruso, Co-Founder and CEO of New to The Street. “We’re combining Wall Street-level insight with storytelling that connects emotionally and visually. Companies are seeing it translate directly into visibility and traction.”

Since 2009, New to The Street has produced thousands of 7-10-minute segments featuring public company CEOs and C-suite leaders, broadcast as sponsored programming on Bloomberg Television and FOX Business. The addition of 27-28-minute documentary specials represents a strategic evolution in media format-now delivering immersive brand narratives that are licensed, broadcast, and featured across a YouTube network with more than 2.5 million subscribers.

Following national TV exposure, these pieces are supported by earned media syndication, social media campaigns, and Times Square billboard placements-providing a 360° distribution model for maximum investor engagement.

“The data is crystal clear-audiences are spending more time with high-quality, long-form content,” added Caruso. “This format allows companies to fully control their narrative, showcase innovation, and build trust-all while generating viewership numbers that rival traditional media.”

For media, sponsorship, or booking inquiries, contact:
Monica Brennan
Monica@NewToTheStreet.com

About New to The Street:
New to The Street is a nationally syndicated financial media platform delivering long-form television interviews, corporate documentaries, and multi-channel distribution across Bloomberg TV, FOX Business, as sponsored programming and one of the largest business YouTube channels in the industry. With over 245 million weekly household reach and 2.54M+ subscribers, the brand is redefining how business stories are told-and seen.

SOURCE: New To The Street

View the original press release on ACCESS Newswire